Inducing ApoE Secretion in Stem Cells for Alzheimer's Treatment
Author Information
Author(s): Zeitouni Suzanne, Ford Brian S, Harris Sean M, Whitney Mandolin J, Gregory Carl A, Prockop Darwin J
Primary Institution: Tulane University Medical School
Hypothesis
Can pharmaceutical agents induce the secretion of ApoE in human mesenchymal stem cells (hMSCs) to provide a therapeutic benefit for Alzheimer's disease?
Conclusion
The study found that pre-treatment with dexamethasone can induce hMSCs to secrete ApoE, which may offer a new therapy for Alzheimer's disease and related conditions.
Supporting Evidence
- Human MSCs did not secrete ApoE under standard culture conditions but did so when treated with dexamethasone.
- ApoE secretion persisted for up to 14 days after withdrawal of the inducing agents.
- Maximal ApoE expression was achieved after 21 days of treatment with dexamethasone or adipo-inductive media.
Takeaway
Scientists figured out how to make special cells in our body produce a helpful protein that can fight diseases like Alzheimer's by using a medicine.
Methodology
The study involved culturing human MSCs and testing various pharmaceutical agents to induce ApoE secretion, measuring the levels over time.
Limitations
The study's findings may not directly translate to in vivo conditions, and the long-term effects of dexamethasone treatment need further investigation.
Participant Demographics
The study used MSCs from 8 donors, including 7 males and 1 female aged 25 to 34.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website